At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 42 enrolled
Drug / intervention
raloxifene +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Raloxifene in Women With AD: Randomized Controlled Trial
In Brief
A Phase 2 clinical trial evaluating raloxifene and Placebo for Alzheimer Disease. Completed, enrolled 42 participants across 4 sites.
Detailed Summary
This is a multisite pilot randomized trial of raloxifene or placebo for the treatment of women with Alzheimer's disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesUnited States
CollaboratorsKaiser Permanente, Indiana University, Southern Illinois University
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2006
First PostedAug 2006
Primary CompletionMar 2011
Study CompletionJan 2012
TodayJul 2026
First PostedAug 24, 2006
Enrollment StartAug 1, 2006
Primary CompletionMar 1, 2011
Study CompletionJan 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 19.9 years ago
Interventions
raloxifenedrug
Raloxifene is a selective estrogen receptor modulator
Placebodrug
Identical appearing placebo